Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 5/20 | 0.46 |
| ▸ | KDR | P35968 | 5/20 | 0.46 |
| ▸ | CA1 | P00915 | 4/20 | 0.46 |
| ▸ | CA2 | P00918 | 4/20 | 0.46 |
| ▸ | CA9 | Q16790 | 4/20 | 0.46 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.42 |
| ▸ | LPL | P06858 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA3 | P07451 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5675377 | 0.89 | PDGFRB (0.58) | PDGFRBKDRCA1CA2CA9 | |
| SCHEMBL423849 | 0.86 | PDGFRB (0.54) | PDGFRBKDRALDH1A1MAPTKDM4E | |
| SCHEMBL7139795 | 0.85 | CA1 (0.48) | PDGFRBKDRCA1CA2CA9 | |
| SCHEMBL29895479 | 0.85 | ALDH1A1 (0.50) | PDGFRBKDRCA1CA2CA9 | |
| SCHEMBL561229 | 0.85 | ALDH1A1 (0.50) | PDGFRBKDRCA1CA2CA9 | |
| SCHEMBL3322268 | 0.85 | LPL (0.45) | PDGFRBKDRCA1CA2CA9 | |
| SCHEMBL15932600 | 0.85 | RAB9A (0.55) | PDGFRBKDRCA1CA2CA9 | |
| SCHEMBL21928146 | 0.85 | MEN1 (0.46) | PDGFRBKDRCA1CA2CA9 | |
| SCHEMBL11908777 | 0.84 | CA1 (0.50) | PDGFRBKDRCA1CA2CA9 | |
| SCHEMBL30874514 | 0.83 | CA1 (0.46) | PDGFRBKDRCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021486-B2 | Coumarin-like cyclic compound as MEK inhibitor and use thereof | CSTONE PHARMACEUTICALS (KY) | 2021-06-01 | — | — | US | disclosed |
| EP-3643308-B1 | COUMARIN-LIKE CYCLIC COMPOUND AS MEK INHIBITOR AND USE THEREOF | CSTONE PHARMACEUTICALS (KY) | 2021-05-19 | — | — | EP | disclosed |
| US-10813930-B2 | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 | INCYTE CORPORATION (US) | 2020-10-27 | — | — | US | disclosed |
| US-10813930-B2 | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 | INCYTE CORPORATION (US) | 2020-10-27 | — | — | US | disclosed |
| US-20200148695-A1 | COUMARIN-LIKE CYCLIC COMPOUND AS MEK INHIBITOR AND USE THEREOF | CSTONE PHARMACEUTICALS (KY) | 2020-05-14 | — | — | US | disclosed |
| EP-3643308-A1 | COUMARIN-LIKE CYCLIC COMPOUND AS MEK INHIBITOR AND USE THEREOF | CSTONE PHARMACEUTICALS (KY) | 2020-04-29 | — | — | EP | disclosed |
| US-20190240220-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | INCYTE CORPORATION | 2019-08-08 | — | — | US | disclosed |
| US-20190240220-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | INCYTE CORPORATION | 2019-08-08 | — | — | US | disclosed |
| EP-2300465-B1 | IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTEX THERAPEUTICS LTD (GB) | 2019-04-17 | — | — | EP | disclosed |
| US-20170165263-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | INCYTE CORPORATION | 2017-06-15 | — | — | US | disclosed |
| WO-2010011620-A1 | 4-PHENOXY-6-ARYL-1H-PYRAZOLO[3,4-D]PYRIMIDINE AND N-ARYL-6-ARYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2010-01-28 | — | — | WO | disclosed |
| WO-2010011620-A1 | 4-PHENOXY-6-ARYL-1H-PYRAZOLO[3,4-D]PYRIMIDINE AND N-ARYL-6-ARYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2010-01-28 | — | — | WO | disclosed |
| US-20100015141-A1 | 4-PHENOXY-6-ARYL-1H-PYRAZOLO[3,4-D]PYRIMIDINE AND N-ARYL-6-ARYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100015141-A1 | 4-PHENOXY-6-ARYL-1H-PYRAZOLO[3,4-D]PYRIMIDINE AND N-ARYL-6-ARYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100015141-A1 | 4-PHENOXY-6-ARYL-1H-PYRAZOLO[3,4-D]PYRIMIDINE AND N-ARYL-6-ARYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2010-01-21 | — | — | US | disclosed |
| WO-2009150240-A1 | IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2009-12-17 | — | — | WO | disclosed |
| EP-2114941-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS FGFR INHIBITORS | Astex Therapeutics Limited (GB) | 2009-11-11 | — | — | EP | disclosed |
| WO-2009047506-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2009-04-16 | — | — | WO | disclosed |
| WO-2008078091-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS FGFR INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008078091-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS FGFR INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11021486-B2 | Coumarin-like cyclic compound as MEK inhibitor and use thereof | MAP3K11, MAP3K15, MAP3K20 | PDGFRB 2721/4885KDR 603/4885CA1 4400/4885 |
| US-20190240220-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | FGFR3, FGFR4, FGFR2 | PDGFRB 23/4885KDR 133/4885CA1 3871/4885 |
| US-10813930-B2 | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 | FGFR3, FGFR4, FGFR2 | PDGFRB 23/4885KDR 133/4885CA1 3871/4885 |
| US-20200148695-A1 | COUMARIN-LIKE CYCLIC COMPOUND AS MEK INHIBITOR AND USE THEREOF | MAP3K11, MAP3K15, MAP3K20 | PDGFRB 2721/4885KDR 603/4885CA1 4400/4885 |
| US-20100015141-A1 | 4-PHENOXY-6-ARYL-1H-PYRAZOLO[3,4-D]PYRIMIDINE AND N-ARYL-6-ARYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | MTOR, PIK3CA, PIK3CD | PDGFRB 300/4885KDR 633/4885CA1 4819/4885 |
| US-20170165263-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | FGFR3, FGFR4, FGFR2 | PDGFRB 23/4885KDR 133/4885CA1 3871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.